Capitol building in Washington
Biotech

A divisive bill seeks to limit biotech investment in China

Two federal lawmakers have introduced a bill seeking to apply the review requirements of the COINS Act to investments in Chinese biotechnology.
Will Maddox Jun 4, 2026 10:54am
EULAR entrance

Cabaletta's autoimmune CAR-T strategy is built on 'durability'

Jun 4, 2026 8:26am
Entry Japan with Clarity Execute with Confidence

PATH-Solution

Brought to you by Alfresa Holdings Corporation
An arrow incrementally going up stairs before pointing straight up Blue background

Innovent, fresh from $1.2B deal, posts key win for CLDN18.2 ADC

Jun 4, 2026 7:47am
highway

Autobahn races toward ph. 3 after midstage bipolar depression win

Jun 4, 2026 11:31am
IPO initial public offering Wall Street

Parabilis preps $413M IPO to fuel desmoid tumor drug into ph. 3

Jun 4, 2026 10:02am
More News

Alnylam pays Inceptive $30M to transform siRNA design

Jun 4, 2026 4:13am
Fierce Pharma

Lilly, Boehringer slash investment plans in Germany

Jun 3, 2026 3:10pm

Regeneron pays $37M, adds $2B in biobucks to expand CytomX pact

Jun 3, 2026 9:48am
Fierce Pharma

At ASCO, China biotech industry cements its coming of age

Jun 3, 2026 8:50am